Join the club for FREE to access the whole archive and other member benefits.

Update on successful dosing of first patient CLXR-001 by Celixir


Key points from article :

The first patient was successfully dosed in cardiomyopathy study.

Announces an update with lead therapeutic candidate CLXR-001 successfully dosed in the Company’s Heartcel clinical trial of its novel iMP cells in patients with cardiomyopathy.

CLXR-001 allows rapid point-of-care use of Celixir’s novel allogeneic (off-the-shelf) iMP cells without the requirement for a cell culture laboratory.

In consultation with the Medicines and Healthcare products Regulatory Agency (MHRA), Celixir has suspended the current Heartcel clinical trial and replace it with a revised protocol.

Professor Stephen Westaby said: “A 2012 investigator-led trial showed no adverse effects and patients are still doing well several years later.”

A significant reduction of scar tissue in the damaged heart muscle conveyed a reduced likelihood of developing heart failure.

Professor Sir Martin Evans added: “We are pioneering a cellular therapy aimed at progressing the heart regeneration field.”

This trial highlights a novel cell therapy with an off-the-shelf product formulation, GMP manufacturing and a UK-approved clinical trial.

Ongoing clinical trials for heart patients with cellular therapy to cure damaged heart muscles

Mentioned in this article:

Click on resource name for more details.


Company discovering breakthrough medicines that change the standard of medical care for patients

Martin Evans

Co-founder, President and Chief Scientific Officer, Celixir

Medicines and Healthcare products Regulatory Agency (MHRA)

Regulates medicines, medical devices and blood components for transfusion in the UK

Stephen Westaby

Chief Medical Advisor, Cardiac, Celixir